title: Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome.
abstract: Imbalance in the metabolites levels which can potentially be related to certain fetal chromosomal abnormalities can stimulate mother's immune response to produce autoantibodies directed against proteins. The aim of the study was to determine the concentration of 9000 autoantibodies in maternal plasma to detect fetal Down syndrome. Method. We performed 190 amniocenteses and found 10 patients with confirmed fetal Down syndrome (15th-18th weeks of gestation). For the purpose of our control we chose 11 women without confirmed chromosomal aberration. To assess the expression of autoantibodies in the blood plasma, we used a protein microarray, which allows for simultaneous determination of 9000 proteins per sample. Results. We revealed 213 statistically significant autoantibodies, whose expression decreased or increased in the study group with fetal Down syndrome. The second step was to create a classifier of Down syndrome pregnancy, which includes 14 antibodies. The predictive value of the classifier (specificity and sensitivity) is 100%, classification errors, 0%, cross-validation errors, 0%. Conclusion. Our findings suggest that the autoantibodies may play a role in the pathophysiology of Down syndrome pregnancy. Defining their potential as biochemical markers of Down syndrome pregnancy requires further investigation on larger group of patients.
authors.affiliation: Department of Perinatology and Obstetrics, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
authors.forename: Karol
authors.initials: K
authors.lastname: Charkiewicz
authors.affiliation: Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
authors.forename: Monika
authors.initials: M
authors.lastname: Zbucka-Kretowska
authors.affiliation: Faculty of Computer Science, Bialystok University of Technology, Wiejska 45A, 15-351 Bialystok, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Goscik
authors.affiliation: Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
authors.forename: Slawomir
authors.initials: S
authors.lastname: Wolczynski
authors.affiliation: Department of Perinatology and Obstetrics, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
authors.forename: Adam
authors.initials: A
authors.lastname: Lemancewicz
authors.affiliation: Department of Perinatology and Obstetrics, Medical University of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
authors.forename: Piotr
authors.identifier: 0000-0001-8955-8198
authors.initials: P
authors.lastname: Laudanski
mesh_terms: D000328:Adult; D000649:Amniocentesis; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002869:Chromosome Aberrations; D002891:Chromosomes, Human, Pair 21; D004314:Down Syndrome / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology*; D005260:Female; D005333:Fetus; D005865:Gestational Age; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D040081:Protein Array Analysis; D012680:Sensitivity and Specificity
chemical_list: D001323:Autoantibodies; D015415:Biomarkers